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parameters, occurrence of urinary tract infection (UTI), number
of incontinence episodes, use of incontinence aids (e.g. absorbent
pads, urinary reservoirs) frequency and number of outpatient
consultations were collected by chart abstraction covering 12
months before and after ﬁrst BTA therapy. RESULTS: Seven
specialized hospitals enrolled 214 patients who received in total
418 BTA therapies between 2000 and 2006. Mean age was 38
years (SD 15), 68% were male. Seventy-seven percent suffered
from NDO due to spinal cord injury, 14% due to spina biﬁda and
5% due to multiple sclerosis. Within 12 months 51% of patients
received one BTA therapy, 41% two and 8% three BTA thera-
pies. On average, time interval between BTA therapies was 8.0
months (SD 4.2). Within 12 months before ﬁrst BTA therapy
63% of patients had incontinence episodes and 68% of patients
UTI, after BTA therapy 28% and 33%, respectively. Incontinence
aids were used by 58% of patients within 12 months before ﬁrst
BTA therapy and in 28% of patients after BTA therapy. In
patients, who had used incontinence aids, mean cost per day and
patient decreased from €2 (SD 2) to €1 (SD 2). Mean drug cost
per patient to treat UTI within 12 months decreased from €163
(SD 242) before treatment to €80 (SD 142) after the start of BTA
therapy. CONCLUSION: Presented data are the ﬁrst data
showing the clinical usefulness of botulinum toxin A under
naturalistic conditions in Germany. Moreover, occurrence of
incontinence and UTI was reduced resulting in lower cost
for incontinence aids and UTI medication.
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OBJECTIVES: Overactive Bladder (OAB) is deﬁned as urgency,
with or without urge incontinence, usually with frequency and
nocturia. The prevalence of OAB in Korea is increasing more than
ever before. It is estimated at about 12.2% in adults aged over 18
years (men 10%, women 14.3%), and 14.9% in adults aged over
40 years (men 11.2%, women 18.4%). The study objective is to
evaluate the cost-effectiveness of Solifenacin compared with Tot-
erodine ER for patients with overactive bladder. METHODS: We
developed a decision-analytic model to estimate treatment pat-
terns, resource utilization, and costs for a six-month period with
a societal perspective. The clinical outcome (percentage reduction
in micturition frequency) and probabilities (Patient Perception of
Bladder Conditions, PPBC) for the 1st cycle were collected from
the literature, and the probabilities of each node for the 2nd cycle
were obtained from the literature and expert opinions through the
administration of a semi-Delphi survey where necessary. The cost
items were limited to drugs, monitoring, OAB induced comor-
bidities, physical therapies, surgery, and traveling to the hospital.
RESULTS: The expected cost of treating OAB patients with
Solifenacin (540,170 won) is 19,872 won less costly compared
with Extended-release Tolterodine (560,042 won). The Solifena-
cin arm also showed greater effectiveness than the Tolterodine
arm in percentage reduction in micturition frequency. When we
conducted a sensitivity analysis on success rate (PPBC) and
outcome (percentage reduction in micturition frequency), the
results showed robust. CONCLUSION: The results from this
study suggest that treatment with Solifenacin dominates
Extended-release Tolterodine in terms of lower cost and greater
effectiveness.
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OBJECTIVES: Icodextrin is a glucose polymer that has been
used to replace traditional glucose in peritoneal dialysis (PD)
solutions due to advantages such as improved ultra-ﬁltration
rates. The objective of this study was to estimate the impact of
icodextrin on quality of life (QoL) in patients with diabetes using
ordinary least square (OLS) regression models. METHODS:
Data were collected from a prospective, randomized, controlled,
open-label clinical trial where patients were assigned to one of
two arms. One arm (GLC) only received glucose-based solutions
(GBS). The other arm (ICO) also received GBS but for the long-
dwell they received icodextrin instead. QoL was measured using
the Spanish version of the KDQOL-SF-1.3. To be included in the
analysis, patients must have completed two QoL surveys at least
90 days apart. Twenty-three out of 29 GLC and 27 out of 30 ICO
patients qualiﬁed for the study. Two OLS regression models were
used to estimate the impact of certain variables on the change in
physical component (PCS) and mental component (MCS) scores.
The dependent variables were calculated as the difference
between the baseline and most recent PCS and MCS from the
QoL surveys. Independent variables included a dummy variable
for the study arm (1 = ICO, 0 = GLC), age, gender, and clinical
variables such as urine volume and blood pressure at baseline.
RESULTS: The regression equation for PCS had an adjusted R2
of 0.335. Patients whose PD therapy included icodextrin
reported signiﬁcantly (p < 0.01) greater improvement in their
PCS than those who only received GBS (5.3 points higher). The
MCS equation had an adjusted R2 of 0.232. There was no
signiﬁcant difference in MCS between the ICO and GBS group.
CONCLUSION: The use of icodextrin in patients with diabetes
on PD had better physical QoL outcomes than those who did not
use icodextrin.
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OBJECTIVES: Tolterodine ER (TER) was granted reimburse-
ment in neurogenic overactive bladder (OAB) patients by the
Belgian Health Authorities in 2003 under the condition that an
observational study be performed that conﬁrms clinically signiﬁ-
cant improvements in health-related quality of life (HRQoL) in
these patients. The results of the study are presented here.
METHODS: A multicentre prospective non-interventional study
was initiated in neurogenic OAB patients who discontinued
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